Los Angeles, USA, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Idiopathic Pulmonary Fibrosis Pipeline Appears Robust with 60+ Key Pharma Companies Actively Working in the Space
The Idiopathic Pulmonary Fibrosis pipeline is very robust, and the market is expected to grow in the coming years as new players will enter into the market and provide good competition to the competitors.
DelveInsight's 'Idiopathic Pulmonary Fibrosis Pipeline Insight, 2021' report offers exhaustive global coverage of available, marketed as well as pipeline therapies in different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Idiopathic Pulmonary Fibrosis pipeline domain.
Some of the significant pointers taken from the Idiopathic Pulmonary Fibrosis Pipeline report:
- DelveInsight's analysis presents Idiopathic Pulmonary Fibrosis Pipeline with 60+ active players in the domain investigating 60+ pipeline therapies.
- Major companies such as Mission Therapeutics, Lung Therapeutics, Theravance Biopharma, Pliant Therapeutics, Vicore Pharma, Galecto Biotech, FibroGen, Roche, Kinarus, Insmed, Avalyn Pharmaceuticals, Bridge Biotherapeutics, and others are developing potential drug candidates to improve the Idiopathic Pulmonary Fibrosis treatment scenario.
- Key Idiopathic Pulmonary Fibrosis pipeline therapies such as DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitil, AP01, BBT-877, and others are under investigation in different phases of clinical trials for the treatment of Idiopathic Pulmonary Fibrosis.
- In July 2021, FibroGen announced that FG-3019, the Company's human monoclonal antibody against connective tissue growth factor (CTGF), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).
- In June 2021, Redx Pharma announced that the first healthy volunteer had been dosed in a Phase I clinical evaluating RXC007, investigational oral therapy for Idiopathic Pulmonary Fibrosis (IPF), and other fibrotic, or scarring-related, conditions.
- In May 2021, ImmunoMet Therapeutics announced that the U.S. Food and Drug Administration (FDA) granted fast track status to IM156, a treatment candidate for idiopathic pulmonary fibrosis (IPF).
- In March 2021, MyMD Pharmaceuticals announced that its lead candidate MYMD-1 for the treatment of several autoimmune and age-related disorders, showed promising efficacy in targeting the root causes of inflammation in Idiopathic Pulmonary Fibrosis.
Request for Sample to know which pharma company is expected to be at the forefront in the coming years @Idiopathic Pulmonary Fibrosis Emerging Therapies and Forecast
The Idiopathic Pulmonary Fibrosis pipeline report offers detailed profiles of the pipeline assets along with the inactive and dormant assets, comparative analysis of clinical and non-clinical stage Idiopathic Pulmonary Fibrosis products, comprehensive assessment of driving, and restraining factors along with the opportunities and risks in the Idiopathic Pulmonary Fibrosis pipeline landscape.
Idiopathic Pulmonary Fibrosis Overview
Idiopathic Pulmonary Fibrosis (IPF) is a chronic lung disorder characterized by thickening, stiffening, and scarring (fibrosis) of tissue within the lungs. Affected individuals develop shortness of breath and progressive lung disease. IPF is classified as a form of idiopathic interstitial pneumonia, which is a group of lung diseases that damage the lungs in a similar manner and occur due to unknown causes. This group of disorders is also known as diffuse parenchymal lung diseases.
The initial characteristic symptom is shortness of breath that is particularly noticeable during exertion, such as exercise. This is known as breathlessness or dyspnea. The exact underlying cause of IPF is not fully understood. The disorder occurs in families and also sporadically. Different factors, including immunologic, environmental, and genetic ones, are thought to play a role in the development of the disorder.
Discover more about the disease, treatments, and pipeline therapies @Idiopathic Pulmonary Fibrosis Pipeline Assessment
Idiopathic Pulmonary Fibrosis Pipeline Drugs
Drug | Company | Phase | MoA | RoA |
DUB program: USP30 Inhibitor | Mission Therapeutics | Preclinical | USP30 Inhibitor | NA |
LTI-03 | Lung Therapeutics | Phase I | Caveolin-1 replacements | Inhalation |
TD-1058 | Theravance Biopharma | Phase I | Transforming growth factor-beta type I receptor antagonists | Inhalation |
PLN-74809 | Pliant Therapeutics | Phase II | Integrin alphavbeta1 inhibitors; Integrin alphaVbeta6 inhibitors | Oral |
GB0139 | Galecto Biotech | Phase II | Galectin 3 inhibitors | Inhalation |
Pamrevlumab | FibroGen | Phase III | Connective tissue growth factor inhibitors | Intravenous |
PRM-151 | Roche | Phase III | Protein replacements; Transforming growth factor beta1 modulators | Intravenous |
C21 | Vicore Pharma | Phase II | Angiotensin type 2 receptor agonists | Oral |
Request for Sample to know more @Idiopathic Pulmonary Fibrosis Pipeline Analysis, Key Companies, and Futuristic Trends
Idiopathic Pulmonary Fibrosis Therapeutics Assessment
The Idiopathic Pulmonary Fibrosis Pipeline report proffers an integral view of the Idiopathic Pulmonary Fibrosis emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.
By Product Type
- Mono
- Combination
- Mono/Combination
By Stage
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
By Route of Administration
- Subcutaneous
- Intravenous
- Oral
- Inhalation
By Molecule Type
- Small molecules
- Peptides
- Recombinant Proteins
- Monoclonal antibodies
By Mechanism of Action
- Transforming growth factor-beta type I receptor antagonists
- Integrin alphavbeta1 inhibitors, Integrin alphaVbeta6 inhibitors
- Galectin 3 inhibitors
- Connective tissue growth factor inhibitors
- Angiotensin type 2 receptor agonists
By Targets
- Transforming growth factor-beta type I receptor
- Integrin alphavbeta1, Integrin alphaVbeta6
- Galectin 3
- Connective tissue growth factor
- Angiotensin type 2 receptor
Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report
- Coverage: Global
- Major Players: Mission Therapeutics, Lung Therapeutics, Theravance Biopharma, Pliant Therapeutics, Vicore Pharma, Galecto Biotech, FibroGen, Roche, Kinarus, Insmed, Avalyn Pharmaceuticals, Bridge Biotherapeutics
- Key Idiopathic Pulmonary Fibrosis Pipeline Therapies: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitil, AP01, BBT-877
For rich insights into emerging therapies and assessment, visit @Idiopathic Pulmonary Fibrosis Pipeline Emerging Novel Therapies
Table of Contents
1 | Introduction |
2 | Executive Summary |
3 | Idiopathic Pulmonary Fibrosis: Overview |
4 | Pipeline Therapeutics |
5 | Late Stage Products (Pre-registration) |
6 | Late Stage Products (Phase III) |
7 | Mid Stage Products (Phase II) |
8 | Early Stage Products (Phase I) |
9 | Pre-clinical Stage Products |
10 | Therapeutic Assessment |
11 | Inactive Products |
12 | Idiopathic Pulmonary Fibrosis- Unmet Needs |
13 | Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers |
14 | Appendix |
15 | About DelveInsight |
Discover more about the scope of the report @Idiopathic Pulmonary Fibrosis Emerging Therapies, Treatments, and Ongoing Clinical Trials
Audit the market before venturing with DelveInsight's Due Diligence Services
Related Reports
Chronic Obstructive Pulmonary Disease Pipeline
DelveInsight's "Chronic Obstructive Pulmonary Disease – Pipeline Insight, 2021," report.
Bronchiolitis Obliterans Syndrome Market
DelveInsight's 'Bronchiolitis Obliterans Syndrome – Market Insights, Epidemiology, and Market Forecast – 2030' report.
Allergic Bronchopulmonary Aspergillosis Market
DelveInsight's "Allergic Bronchopulmonary Aspergillosis - Market Insights, Epidemiology, and Market Forecast-2030" report.
Browse Through Our Blog Posts
Cystic Fibrosis Market: A Rapidly Expanding Playing Field for Mid-Cap Pharma
Cystic Fibrosis is a rare inherited disorder that causes loss of lung function and damages the digestive system. It has a higher prevalence in the Caucasian population.
Chronic Respiratory Diseases (CRDs) and Their Prolonged Impact on the Quality of Life
Today, the increasing prevalence of Chronic Respiratory Diseases (CRDs) is one of the leading health challenges worldwide. CRDs affect hundreds of millions of people and cause huge mortality, morbidity, immense socio-economic burden, and disability-adjusted life years (DALYs).
Cystic Fibrosis Drug Market: Emerging drugs that may improve lung infections
Cystic fibrosis (CF) manifests as a clinical syndrome characterized by chronic sinopulmonary infection as well as by gastrointestinal, nutritional, and other abnormalities.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
